Brind.
  1. Medicus Pharma secured an ADC development deal with Pfizer and is advancing its SkinJect 005 study for FDA approval.

Pfizer records R&D charge related to CD228V license acquisition

1 report, 1 independent Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Pfizer made a payment for the CD228V license related to drug development. According to financial reporting, the company recorded a $10 million acquired research and development charge tied to the CD228V asset during the first nine months of 2026.

From fool.com

Why it matters

Some supportBrind's analysis of the reports

The acquisition of the CD228V license adds a new asset to Pfizer's portfolio. The company reported having a cash balance of $5 million as of September 30, 2026, while also incurring a net loss of $35.9 million for the nine months ended September 30, 2026.

Medicus Pharma secured an ADC development deal with Pfizer and is advancing its SkinJect 005 study for FDA approval.

From fool.com

Who's involved

  • PfizerPharmaceutical company that acquired the CD228V license and recorded the related R&D charge

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

Keep exploring

Part of

Medicus Pharma secured an ADC development deal with Pfizer and is advancing its SkinJect 005 study for FDA approval. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped